Current status of targeted therapies in advanced gastric cancer

Ferdinando De Vita, Francesco Giuliani, Nicola Silvestris, Sabrina Rossetti, Antonio Pizzolorusso, Giuseppe Santabarbara, Gennaro Galizia, Giuseppe Colucci, Fortunato Ciardiello, Michele Orditura

Research output: Contribution to journalArticlepeer-review


Introduction: In metastatic gastric cancer, chemotherapy is the standard treatment because it prolongs survival when compared to best supportive care alone. However, even after the use of more effective regimens, the overall survival remains disappointing, justifying the need for new treatment options. Areas covered: Areas covered in this review include the most common molecular pathways, which have provided novel targets in gastric cancer therapy. These therapeutic strategies include EGFR inhibitors, anti-angiogenic agents, cell cycle inhibitors and apoptosis promoters. Expert opinion: Several mAbs and kinase inhibitors, especially those targeting EGFR and VEGF/VEGFR, have already demonstrated promising activity in gastric cancer. The Phase III ToGA trial reported an increase in overall survival for patients with human EGF receptor (HER)2-positive gastric cancer treated with chemotherapy and trastuzumab compared to chemotherapy alone. This means that accurate HER2 testing in gastric cancer is necessary. Final data of ongoing trials with novel agents will be critical to further progress with this cancer.

Original languageEnglish
JournalExpert Opinion on Therapeutic Targets
Issue numberSUPPL.2
Publication statusPublished - Apr 2012


  • anti-EGFR drugs
  • bevacizumab
  • cetuximab
  • trastuzumab

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine


Dive into the research topics of 'Current status of targeted therapies in advanced gastric cancer'. Together they form a unique fingerprint.

Cite this